p. 4803−4812
2476-762X
Vol.16/No.12
p. 4813−4820
2476-762X
Vol.16/No.12
p. 4821−4824
2476-762X
Vol.16/No.12
p. 4825−4832
2476-762X
Vol.16/No.12
p. 4833−4837
2476-762X
Vol.16/No.12
2cm. For endometrial cancers, there is much experience on it. Given accurate pretreatmentassessment, hormonal therapy is feasible management option to preserve fertility in young patients with earlystage lesions that limited to the endometrium and well differentiated. High dose progestin have been applied,oral medroxyprogesterone acetate (MPA), 250-500mg/day, megestrol acetate 160-480mg/day. Other therapiesthat have been used in a limited number of cases include GnRH analog, intrauterine devices (IUDS) containingprogestogen, usually combination of these therapies. All patients should be followed up by ultrasound and/orMRI evaluation, and endometrial curettage at intervals of 3 months. With ovarian cancer, in China, fertilitypreservingsurgery in patients with stage IA (grade G1) of epithelial ovarian tumor and patients with germ celltumor and borderline ovarian tumor have been successfully performed.]]>
p. 4839−4841
2476-762X
Vol.16/No.12
p. 4843−4847
2476-762X
Vol.16/No.12
p. 4849−4852
2476-762X
Vol.16/No.12
p. 4853−4858
2476-762X
Vol.16/No.12
p. 4859−4862
2476-762X
Vol.16/No.12
p. 4863−4867
2476-762X
Vol.16/No.12
p. 4869−4872
2476-762X
Vol.16/No.12
p. 4873−4880
2476-762X
Vol.16/No.12
p. 4881−4883
2476-762X
Vol.16/No.12
p. 4885−4890
2476-762X
Vol.16/No.12
p. 4891−4894
2476-762X
Vol.16/No.12
p. 4895−4900
2476-762X
Vol.16/No.12
p. 4901−4903
2476-762X
Vol.16/No.12
p. 4905−4908
2476-762X
Vol.16/No.12
0.05). After treatment, APTT went down and PAG was gradually onthe rise in control group, while PAG down and APTT on the rise increasingly in observation group. Significantdifferences were presented between two groups as well as before and after treatment (p<0.01). Both PSA and Tlevels were decreased significantly in two groups after treatment (p<0.01), but there was no statistical significantbetween two groups (p>0.05). Conclusions: Application of endocrinotherapy in prostate cancer can easily leadto occurrence of cardiovascular disease, but cardiovascular complications can be prevented by aspirin, withoutaffecting the effect of endocrinotherapy.]]>
p. 4909−4913
2476-762X
Vol.16/No.12
T(p.Ser1811Leu), two c.3926_3930delAAAAG (p.Glu1309AspfsX4), c.3921_3924delAAAA (p.Ile1307MetfsX13),c3184_3187delCAAA(p.Gln1061AspfsX59) and c4127_4126delAT (p.Tyr1376LysfsX9), respectively, and alldeletion mutations resulted in a premature stop codon. At the same time, we found c.3921_3924delAAAA andtwo c.3926_3930delAAAAG are located in AAAAG short tandem repeats, c3184_3187delCAAA is located in theCAAA interrupted direct repeats, and c4127_4128 del AT is located in the 5’-CCTGAACA-3’ ,3’-ACAAGTCC-5palindromes (inverted repeats) of the APC gene. Furthermore, deletion mutations are mostly located at condon1309. Conclusions: Though there were no novel mutations found as the pathogenic gene of FAP in this study,we found nucleotide sequence containing short tandem repeats and palindromes (inverted repeats), especiallythe 5 bp base deletion at codon 1309, are mutations in high incidence area in APC gene.]]>
p. 4915−4920
2476-762X
Vol.16/No.12
p. 4921−4926
2476-762X
Vol.16/No.12
p. 4927−4935
2476-762X
Vol.16/No.12
p. 4937−4944
2476-762X
Vol.16/No.12
75th) had significantly (p< 0.05) decreased risk of breast cancer having OR=0.06 (CI: 0.02-0.15),when compared to the lowest quartile. Conclusions: We demonstrated a statistically significant association ofelevated serum adiponectin with decreased risk of breast cancer. This signifies a protective role of adiponectinvia an intricate mechanism of masking mitogenic growth factors in breast carcinogenesis.]]>
p. 4945−4948
2476-762X
Vol.16/No.12
p. 4949−4954
2476-762X
Vol.16/No.12
p. 4955−4958
2476-762X
Vol.16/No.12
p. 4959−4964
2476-762X
Vol.16/No.12
p. 4965−4969
2476-762X
Vol.16/No.12
p. 4971−4975
2476-762X
Vol.16/No.12
p. 4977−4980
2476-762X
Vol.16/No.12
p. 4981−4985
2476-762X
Vol.16/No.12
p. 4987−4991
2476-762X
Vol.16/No.12
p. 4993−4996
2476-762X
Vol.16/No.12
p. 4997−4999
2476-762X
Vol.16/No.12
p. 5001−5004
2476-762X
Vol.16/No.12
p. 5005−5006
2476-762X
Vol.16/No.12
p. 5007−5011
2476-762X
Vol.16/No.12
p. 5013−5018
2476-762X
Vol.16/No.12
10cc). Materials and Methods: Ten AS patients were immobilized using BrainLab mask.They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour targetand organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic planswere optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III andfinal dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All ASpresented in this study were treated with VMAT based HSRT to a total dose of 25Gy in 5 fractions (5fractions/week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99%of PTV volume (D99) receives 100% of prescription dose (25Gy), while dose to OAR’s were kept below thetolerance limits. Dose–volume histograms (DVH) were analyzed to assess plan quality. Treatments were deliveredusing upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment qualityassurance measurements were carried out to report on quality of delivery. Point dosimetry was performed usingthree different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plasticscintillator detector (PSD) which have measuring volume of 0.13 cm3, 0.009 cm3 and 0.002 cm3 respectively.Results: Average PTV volume of AS was 11.3cc (±4.8), and located in eloquent areas. VMAT plans providedcomplete PTV coverage with average conformity index of 1.06 (±0.05). OAR’s dose were kept below tolerancelimit recommend by American Association of Physicist in Medicine task group-101(brainstem V0.5cc < 23Gy,cochlea maximum < 25Gy and Optic pathway <25Gy). PSD resulted in superior dosimetric accuracy comparedwith other two detectors (p=0.021 for PSD]]>
p. 5019−5024
2476-762X
Vol.16/No.12
p. 5025−5030
2476-762X
Vol.16/No.12
p. 5031−5036
2476-762X
Vol.16/No.12
p. 5037−5041
2476-762X
Vol.16/No.12
p. 5043−5047
2476-762X
Vol.16/No.12
p. 5049−5052
2476-762X
Vol.16/No.12
p. 5053−5058
2476-762X
Vol.16/No.12
p. 5059−5062
2476-762X
Vol.16/No.12
p. 5063−5067
2476-762X
Vol.16/No.12
0.05). The frequencies of allele T (major allele)in HCC patients, CHB patients and healthy controls were 51.4%, 58.6% and 61.4%, respectively, whereas thefrequencies of C allele (minor allele) were 48.6%, 41.4% and 38.6%. The C allele frequency was higher in HCCwhen compared with CHB patients (odds ratio (OR)=1.34, 95% confidence interval (CI)=1.02-1.74, P=0.032).The genotype of SNP rs1053004 (CC versus TT+TC) was significantly associated with an increased risk whencompared with CHB patients (OR=1.83, 95% CI=1.13-2.99, P=0.015). In addition, we observed a similar trendof association when comparing HCC patients with healthy controls (OR=1.77, 95% CI=1.07-2.93, P=0.025) andall controls (OR=1.81, 95% CI=1.19-2.74, P=0.005). These findings suggest that the SNP rs1053004 in STAT3might contribute to HCC susceptibility and could be used as a genetic marker for HCC in the Thai population.]]>
p. 5069−5073
2476-762X
Vol.16/No.12
p. 5075−5079
2476-762X
Vol.16/No.12
p. 5081−5084
2476-762X
Vol.16/No.12
p. 5085−5088
2476-762X
Vol.16/No.12
p. 5089−5094
2476-762X
Vol.16/No.12
p. 5095−5099
2476-762X
Vol.16/No.12
p. 5101−5106
2476-762X
Vol.16/No.12
p. 5107−5110
2476-762X
Vol.16/No.12
p. 5111−5113
2476-762X
Vol.16/No.12
p. 5115−5118
2476-762X
Vol.16/No.12
p. 5119−5124
2476-762X
Vol.16/No.12
p. 5125−5135
2476-762X
Vol.16/No.12